The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.
TROPiCS-02 Data Reinforce Role of Sacituzumab Govitecan as a SOC in HR+ Breast Cancer
August 29th 2023Sara M. Tolaney, MD, MPH, highlights updated survival and safety data seen with sacituzumab govitecan in patients with hormone receptor–positive, HER2-negative breast cancer; underscores how Trop-2 and HER2 testing is not necessarily needed for this agent in this population at this time; and shares how ongoing efforts are exploring the utilization of this agent earlier in the treatment course.
Read More
The Future of HER2+ Breast Cancer Treatment
Panelists wrap up their discussion on HER2+ breast cancer by summarizing the most exciting recent advances in the field and their hopes for the future of treatment.
Watch
Looking Towards The Future of HR+/HER2- Breast Cancer
The expert panel discusses ongoing research and offers closing thoughts on the future of HR+/HER2- breast cancer treatment.
Watch
Practical Considerations for ADC Selection in HR+/HER2- mBC
Panelists share clinical insight into how to approach treatment selection among ADCs in HR+/HER2- metastatic breast cancer both now and in the future, given the currently available options and additional ADCs in development.
Watch
Novel ADCs Must Keep Up With Moving Targets in Metastatic Breast Cancer
August 22nd 2023Barbara Pistilli, MD, discusses the mechanism of action of novel ADCs, the ways in which ADC targets in breast cancer can change over time, and how future research may pave the way for individualized treatment with this class of agents.
Read More
Barriers to Optimal Care in Patients With HR+/HER- Breast Cancer
August 22nd 2023Key opinion leaders detail various barriers to optimal care for patients with HR+/HER2- breast cancer, including transportation issues, financial difficulties, lack of family support, and challenges in coordinating care among different medical specialists.
Watch
Dr Tarantino on Patient Awareness of the Platinum Shortage in Breast Cancer
August 18th 2023Paolo Tarantino, MD, discusses typical conversations oncologists should have with patients regarding the platinum chemotherapy shortage, as well as the importance of honest communication about treatment regimen changes.
Watch
Patient Profile 3: Metastatic HER2+ BC
Dr Kaklamani presents a profile of a patient with HER2+ breast cancer and liver metastases who had disease progression after first-line chemotherapy and a solitary new brain metastasis after second-line T-DM1.
Watch
Patient Profile 2: Early Stage HER2+/HR- BC
Melinda L. Telli, MD, presents a profile of a patient with early stage breast cancer with residual nodal disease after neoadjuvant chemotherapy and surgery, whose tumor was initially HER2+ but became triple-negative after treatment.
Watch
Tucatinib/Letrozole/Palbociclib Combination Demonstrates Meaningful Efficacy in HR+/HER2+ mBC
August 16th 2023Treatment with the all-oral triplet of tucatinib, letrozole, and palbociclib yielded clinically meaningful efficacy results and had an acceptable safety profile in patients with hormone receptor–positive, HER2-positive metastatic breast cancer.
Read More
Data Updates on Sacituzumab Govitecan
Dr Gadi discusses recent data updates on the TROP-2–directed antibody-drug conjugate (ADC) sacituzumab govitecan (SG), including analyses performed in patients with HER2-low disease.
Watch
Biomarker Testing Practices in HR+/HER2- Breast Cancer
Experts on HR+/HER2- breast cancer discuss biomarker testing approaches, including sampling considerations and timing of testing.
Watch
BAT8006 Elicits Disease Control, Safety in Advanced Ovarian Cancer and Other Solid Tumors
August 14th 2023Treatment with the folate receptor–α antibody-drug conjugate BAT8006 led to responses with a manageable safety profile in patients with advanced solid tumors, including ovarian cancer, breast cancer, and cervical cancer.
Read More
Patient Profile 1: Early Stage HER2+/HR+ BC
Virginia G. Kaklamani, MD, DSc, presents a patient profile of early stage HER2+ breast cancer with residual nodal disease after neoadjuvant chemotherapy and surgery.
Watch
Typical Approaches for Treatment Selection in the Third Line and Beyond
Experts share their go-to regimens in the third-line and higher setting of HER2+ metastatic breast cancer, and touch on the factors that support their decision-making.
Watch
Dr Tarantino on the Effects of Platinum Chemotherapy Shortages in Breast Cancer
August 9th 2023Paolo Tarantino, MD, discusses how the ongoing shortages of carboplatin and cisplatin in the United States are affecting patients with breast cancer and the importance of overcoming this wave of shortages and preventing this issue from recurring in the future.
Watch
Real-World Data Support Role of Palbociclib in HR+/HER2– Metastatic Breast Cancer
August 9th 2023Bhuvaneswari Ramaswamy, MD, and colleagues highlight treatment for patients with HR-positive breast cancer, discuss the role of pembrolizumab plus chemotherapy in early-stage triple-negative breast cancer, and expand on unmet needs for patients with metastatic HER2-positive breast cancer.
Read More
Dr Batra-Sharma on Conducting a Clinicopathologic Investigation Into Metaplastic Breast Cancer
August 9th 2023Hemali Batra-Sharma, MD, discusses a single-institution, retrospective clinicopathologic analysis of patients with metaplastic breast cancer, findings from which were presented at the 2023 ASCO Annual Meeting.
Watch
Novel PROTACs Broaden the HR+ Breast Cancer Investigational Landscape
August 9th 2023Seth Wander, MD, PhD, discusses evidence to support the investigation of PROTACs in patients with hormone receptor–positive breast cancer; preliminary efficacy and safety findings with vepdegestrant; and potential strategies for targeting acquired ESR1 resistance mutations.
Read More